Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 8;16(5):629.
doi: 10.3390/pharmaceutics16050629.

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

Celia Gómez-Labrador  1 , Elena Ricart  2 , Marisa Iborra  3 , Eva Iglesias  4 , María Dolores Martín-Arranz  5 , Luisa de Castro  6 , Ruth De Francisco  7 , Francisco Javier García-Alonso  8 , Ana Sanahuja  9 , Carla J Gargallo-Puyuelo  10 , Francisco Mesonero  11 , María José Casanova  1 , Míriam Mañosa  12 , Montserrat Rivero  13 , Marta Calvo  14 , Mónica Sierra-Ausin  15 , Carlos González-Muñoza  16 , Xavier Calvet  17 , Santiago García-López  18 , Jordi Guardiola  19 , Lara Arias García  20 , Lucía Márquez-Mosquera  21 , Ana Gutiérrez  22 , Yamile Zabana  23 , Mercè Navarro-Llavat  24 , Rufo Lorente Poyatos  25 , Marta Piqueras  26 , Leyanira Torrealba  27 , Fernando Bermejo  28 , Ángel Ponferrada-Díaz  29 , José L Pérez-Calle  30 , Manuel Barreiro-de Acosta  31 , Coral Tejido  32 , José Luis Cabriada  33 , Ignacio Marín-Jiménez  34 , Óscar Roncero  35 , Yolanda Ber  36 , Luis Fernández-Salazar  37 , Blau Camps Aler  38 , Alfredo J Lucendo  39 , Jordina Llaó  40 , Luis Bujanda  41 , Carmen Muñoz Villafranca  42 , Eugeni Domènech  12   43 , María Chaparro  1 , Javier P Gisbert  1
Affiliations

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

Celia Gómez-Labrador et al. Pharmaceutics. .

Abstract

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.

Keywords: Crohn’s disease; biologics; biosimilars; inflammatory bowel disease; positioning; targeted therapy; trends; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Elena Ricart has received support for congress and conference attendance, speaker fees, research support or consulting fees from MSD, Abbvie, Ferring, Janssen, Otsuka, Pfizer, Takeda, Galapagos, Kern Pharma and Fresenius. Marisa Iborra has served as speaker for and has received consulting fees and research support from Janssen, Takeda, MSD, Kern, Ferring, Otsuka and Chiesi, during the conduct of the study. Eva Iglesias has received support for conference attendance, speaker fees, research support and consulting fees from AbbVie, Adacyte, Dr Falk Pharma, FAES Pharma, Ferring, Janssen, Pfizer and Takeda. María Dolores Martín-Arranz has received consulting and/or speaker fees from AbbVie, Pfizer, Takeda, Janssen, Tillotts Pharma and Galapagos; and has received research funding from Abbvie, Janssen and Pfizer. Ana Sanahuja Martínez has received support for conference attendance and educational funding from AbbVie, Takeda, Janssen, Adacyte and Ferring. Carla J. Gargallo-Puyuelo has received consulting and/or speaker fees from AbbVie, Takeda, and Janssen. María José Casanova has received research or education funding from Pfizer, Takeda, Janssen, MSD, Ferring, Abbvie, Biogen, Lilly, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi y Norgine. Montserrat Rivero has served as a speaker or advisory member from Takeda, Janssen, Ferring and Pfizer. Marta Calvo Moya has received grants for conference attendance, speaker fees, research support and consultancy fees from AbbVie, MSD, Takeda, Janssen, Pfizer, Lilly, Shire, Chiesi, DrFalk Pharma, Faes Pharma, Ferring, Kern Pharma y Tillotts Pharma. Mónica Sierra Ausín has received support for conference attendance, as speaker from Janssen, Takeda, MSD, Ferring, Abbvie and Pfizer. Xavier Calvet has received grants for research from Abbvist, MSD, Vifor, Janssen, Khern fees for advisory boards form Abbvie, MSD, Takeda, Pfizer, Janssen AND VIFOR and has given lectures for Abbvie, MSD, Janssen, Pfizer, Takeda, Shire and Allergan. Santiago García-López has served as a speaker or has received research or education funding or advisory fees from AbbVie, Janssen, Lilly, Pfizer y Takeda. Jordi Guardiola has served as a speaker or has received research or education funding or advisory fees from AbbVie, MSD, Celltrion, Galapagos, GoodGut, Janssen, Kern Pharma, Roche, Pfizer, Sandoz, Takeda and General Electric Healthcare. Lucía Márquez-Mosquera has served as a speaker and consultant or has received research support from AbbVie, Kern Pharma, Janssen, Takeda, Galapagos, Pfizer, Dr. Falk Pharma and Tillots. Ana Gutiérrez has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Sandoz, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi and Otsuka Pharmaceutical. Yamile Zabana has received support for conference attendance, speaker fees, research support and consulting fees from AbbVie, Adacyte, Almirall, Amgen, Dr Falk Pharma, FAES Pharma, Ferring, Janssen, MSD, Otsuka, Pfizer, Shire, Takeda, Galapagos, Boehringer Ingelheim and Tillots. Mercè Navarro has served as a speaker or has received research or education funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Ferring, Dr. Falk Pharma, Tillotts Pharma, Celltrion Healthcare, and Biogen. Rufo Lorente has served as a speaker, or has received research or education funding from Abbvie, Pfizer, Takeda, Janssen. Marta Piqueras has served as a speaker or has received research or education funding from Takeda, Abbvie, FAES Pharma and Janssen. Fernando Bermejo has served as a speaker, consultant or advisory member for or has received research funding from MSD, Abbvie, Takeda, Janssen, Pfizer, Biogen, Amgen, Galápagos, Ferring, Faes Farma, Tillotts Pharma, Chiesi and Vifor Pharma. Angel Ponferrada-Díaz has served as a speaker, a consultant or advisory member from MSD, Abbvie, Takeda and Janssen. José L Perez-Calle has served as consultant and/or speaker or has received education funding from AbbVie, Biogen, Takeda, Janssen, Tillotts Pharma and Faes Farma. Manuel Barreiro-de Acosta has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, GALAPAGOS, Pfizer, Sandoz, Biogen, Fresenius, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma. José Luis Cabriada served as consultant or received research funding to Adacyte, MSD, Takeda, Pfizer, Kern pH, Janssen, Abbvie, Chiesi and Ferring. Ignacio Marín-Jiménez has served as a speaker, a consultant and advisory member for or has received research funding from Abbvie, Amgen, Chiesi, Dr. Falk Pharma, Faes Farma, Ferring, Fresenius, Galapagos, Gebro Pharma, Janssen, Kern Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sandoz, Shire Pharmaceuticals, Takeda, Tillotts Pharma, and Vifor Pharma. Luis Fernández Salazar has received support for conference attendance and research from AbbVie, FAES, Fering, Janssen and Takeda. Eugeni Domènech has served as a speaker or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Galapagos, Gilead, GoodGut, Imidomics, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda and Tillots. María Chaparro has served as a speaker, as consultant or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Biogen and Gilead. Javier P. Gisbert has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. The rest of the authors have nothing to declare.

Figures

Figure 1
Figure 1
(a) Distribution of the use of targeted therapies for inflammatory bowel disease in Spain from 2015 to 2021. Values are provided as %. Inflammatory bowel disease (IBD); (b) evolution of targeted therapies prescription for inflammatory bowel disease (including originator and biosimilars) throughout the study period in Spain.
Figure 2
Figure 2
Prescription of targeted therapies used in Crohn’s disease (a) and in ulcerative colitis (b) per year in 1st and 2nd LoT. Crohn’s disease (CD); ulcerative colitis (UC); line of treatment (LoT).
Figure 3
Figure 3
Treatment change distribution for Crohn’s disease (a) and ulcerative colitis (b) in different lines of treatment (LoT), including originator and biosimilars. Chart shows changes from 1st LoT to 2nd LoT, and from 2nd LoT to 3rd LoT. Values are provided as number of patients (n).
Figure 4
Figure 4
Trends in the use of biosimilars of each anti-TNF targeted therapy (infliximab and adalimumab) relative to their originals in inflammatory bowel disease from 2015 to 2021. Values of the graph are provided as %.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zhao M., Gönczi L., Lakatos P.L., Burisch J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J. Crohn’s Colitis. 2021;15:1573–1587. doi: 10.1093/ecco-jcc/jjab029. - DOI - PubMed
    1. Honap S., Cunningham G., Tamilarasan A.G., Irving P.M. Positioning Biologics and New Therapies in the Management of Inflammatory Bowel Disease. Curr. Opin. Gastroenterol. 2019;35:296–301. doi: 10.1097/MOG.0000000000000546. - DOI - PubMed
    1. Burisch J., Zhao M., Odes S., De Cruz P., Vermeire S., Bernstein C.N., Kaplan G.G., Duricova D., Greenberg D., Melberg H.O., et al. The Cost of Inflammatory Bowel Disease in High-Income Settings: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 2023;8:458–492. doi: 10.1016/s2468-1253(23)00003-1. - DOI - PubMed
    1. Zhao M., Sall Jensen M., Knudsen T., Kelsen J., Coskun M., Kjellberg J., Burisch J. Trends in the Use of Biologicals and Their Treatment Outcomes among Patients with Inflammatory Bowel Diseases—A Danish Nationwide Cohort Study. Aliment. Pharmacol. Ther. 2022;55:541–557. doi: 10.1111/apt.16723. - DOI - PubMed
    1. Sedano R., Almradi A., Ma C., Jairath V., Feagan B.G. Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. Curr. Treat. Options Gastroenterol. 2020;18:442–461. doi: 10.1007/s11938-020-00299-7. - DOI

LinkOut - more resources